US FDA rejects Qutenza in HIV-PN; NeurogesX slashes workforce by 57%
This article was originally published in Scrip
The news of the US FDA's rejection of NeurogesX's Qutenza (capsaicin 8%) patch as a therapy to manage HIV-associated peripheral neuropathy (HIV-PN) not only affected the San Mateo, California-based firm's shares on 8 March – which fell 20%, or 13 cents, to close at 53 cents – but also the company's workforce, which is being slashed by 57%.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.